Live tape
Top 8, mentions 7d9,388TSLA1,985 mentions▲ +0.05GOOGL1,524 mentions▲ +0.04NVDA1,142 mentions▲ +0.07CRWV1,134 mentions▲ +0.03SPCX1,019 mentions▲ +0.07QQQ992 mentions▲ +0.04META796 mentions▲ +0.05NBIS796 mentions▲ +0.05

Equity · Healthcare

RYTM

NASDAQ

Rhythm Pharmaceuticals, Inc.

$107 +0.94% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close)
Price · Chart

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for RYTM to draw a line in its place.

Track this symbol on TradingView TradingView chart
Market cap $7.4B
52-week range $75.84 – $118
Avg volume 260.7K

as of Jul 17, 2026

RYTM insider trades

SEC Form 4 · last 90 days · newest reported trade 14 Sep 2026
Open-market buys 0
Open-market sells 6
Net sold $28.80M
Non-trade filings 5
Date Insider Type Shares Value
14 Sep 2026 Meeker David P President and CEO Sell 50,000 $5.13M
31 Aug 2026 Smith Hunter C Chief Financial Officer Sell 62,774 $6.62M
13 Aug 2026 Lee Jennifer Kayden EVP, Head of North America Sell 75,834 $8.90M
13 Aug 2026 Garfield Alastair Chief Scientific Officer Sell 7,763 $913K
13 Aug 2026 Shulman Joseph Chief Technical Officer Sell 5,079 $608K
12 Aug 2026 Mazabraud Yann EVP, Head of International Sell 57,000 $6.62M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
14 Sep 2026 Meeker David P President and CEO Option exercise 50,000 $303K
31 Aug 2026 Smith Hunter C Chief Financial Officer Option exercise 57,187 $1.47M
13 Aug 2026 Lee Jennifer Kayden EVP, Head of North America Option exercise 56,601 $997K
13 Aug 2026 Shulman Joseph Chief Technical Officer Option exercise 2,024 $14K
12 Aug 2026 Mazabraud Yann EVP, Head of International Option exercise 46,625 $317K

RYTM reported financials

SEC EDGAR XBRL SEC EDGAR

RYTM reported revenue of $189.8M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$196.5M.

Figure Reported Period
Revenue $189.8M 31 Dec 2025 fiscal year
Net income −$196.5M 31 Dec 2025 fiscal year
Diluted EPS −$3.11 31 Dec 2025 fiscal year
Total assets $437.3M 30 Jun 2026 at period end
Total equity $103.0M 30 Jun 2026 at period end

RYTM earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.73 —
31 Mar 2026 Q1 2026 −$0.83 —
31 Dec 2025 FY 2025 −$3.11 —
30 Sep 2025 Q3 2025 −$0.82 —
30 Jun 2025 Q2 2025 −$0.75 —
31 Mar 2025 Q1 2025 −$0.81 —
31 Dec 2024 FY 2024 −$4.34 —
30 Sep 2024 Q3 2024 −$0.73 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

RYTM institutional holders

SEC Form 13F SEC EDGAR

12 of the 45 institutional funds we track reported a RYTM position for the quarter ended 30 Jun 2026 — a combined $892.4M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 5,604,483 $622.3M
Citadel Advisors Held (±25%) −10.9% shares 1,263,652 $140.3M
Point72 Asset Management Trimmed −51.1% shares 414,210 $46.0M
Millennium Management Trimmed −29.9% shares 316,719 $35.2M
Duquesne Family Office New position 203,618 $22.6M
Renaissance Technologies Trimmed −73.5% shares 68,281 $7.6M
AQR Capital Management Held (±25%) −0.1% shares 59,208 $6.6M
Man Group Added +1,162.8% shares 50,788 $5.6M
D. E. Shaw & Co. Held (±25%) −7.6% shares 30,168 $3.3M
Tudor Investment Corp Trimmed −29.3% shares 13,886 $1.5M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

RYTM fails-to-deliver

SEC CNS data SEC

On 30 Sep 2026, 43 shares of RYTM failed to deliver (about $4K).

Settlement date Shares failed Notional % of shares out
30 Sep 2026 43 $4K <0.001%
23 Sep 2026 2 $199 <0.001%

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARValuation computed from SEC EDGAR filings